Pepti review

Nobody here will tell you what a quarter dose costs. Pepti publishes one figure per product for a supply it describes as roughly thirty days, says your provider sets the exact dose and that yours may vary, and then says nothing at all about what a different dose does to the price. Credit where it is due, and there is more of it than usual: the charge is genuinely one-off rather than a subscription, the shipping list names all thirty-six states, the reviewing physician is named, and the efficacy claims are footnoted to real trials with the right durations and sample sizes. Two things will cost you if you misread them. It sells compounded retatrutide alongside the rest, and retatrutide is approved nowhere for anything — a different decision from buying a compounded copy of an approved drug. And semaglutide is sold orally only, above the price of the tirzepatide injection.

Vs median

Not comparable — no per-month rate is published — the verified string carries no monthly figure

Market

$59–$1,300/mo is the full published spread on this site

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Optional

Pricing

Flat at every dose

Pepti does not publicly identify the pharmacy that fills its prescriptions. Bloodwork is offered but not required. A clinician review is included in the price.

Pepti sells compounded GLP-1s as one-time purchases rather than subscriptions, with the medication, the clinical review and shipping in a single figure and a roughly thirty-day supply per order. Semaglutide is offered orally only; tirzepatide is sold as both an injection and an oral. It publishes a full 36-state shipping list, names its reviewing physician, and cites its efficacy claims to specific trials with correct sample sizes and durations. The operating entity, pepti LLC, describes itself as "a technology platform and… not a healthcare provider, pharmacy, or prescriber". It also sells compounded retatrutide, a molecule with no FDA approval for any indication.

IT SELLS COMPOUNDED RETATRUTIDE at $479, badged "Popular". Retatrutide is not approved by the FDA for any indication, which is a different decision from buying a compounded copy of an approved drug

• NO MILLIGRAM FIGURE SITS BEHIND ANY PRICE. The page says the provider sets your exact dose and that yours may vary, and never says what the price does when the dose changes — so a low-dose buyer cannot tell whether the single figure covers them or overcharges them
• A "~30-day supply" is approximate in the site's own wording, so the interval between charges is not fixed
• There is no injectable semaglutide in the catalog — semaglutide is sold orally only, at $299 against $239 for the tirzepatide injection
• The company describes itself as a technology platform rather than a healthcare provider, pharmacy or prescriber
• No compounding pharmacy is named, only "independent FDA-registered 503A or 503B compounding pharmacies"
• No LegitScript seal number is published
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

Pepti is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• Our full Pepti microdose write-up
• What the evidence actually shows
• What microdosing GLP-1 costs
• Low dose vs full dose
• What a flat price costs at a low dose
• The true annual cost of a plan